Skip to main content

Month: September 2025

Karbon Acquires Aider to Deliver the Future of AI-Powered Accounting and Bookkeeping

The acquisition brings automation and AI insights to help firms close books faster, cut workloads, and focus on higher-value client work. SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) — Karbon, the global leader in practice management software for accounting, bookkeeping, tax and audit firms, today announced its acquisition of Aider, a pioneer in AI-powered advisory and reporting technology. The acquisition accelerates Karbon’s vision to transform the accounting profession through AI. Aider’s cutting-edge solution is already trusted by firms across the United States, Canada, Australia, and New Zealand for automating time-consuming bookkeeping and advisory workflows like reconciliations and period close, while delivering real-time client insights and predictive reporting. By integrating Aider’s capabilities into Karbon, firms will...

Continue reading

Terra Innovatum and GSR III Acquisition Corp. Remind Shareholders to Vote and Approve the Business Combination Prior to the October 7 Extraordinary General Meeting of Shareholders

GSRT shareholders are encouraged to use their voice and vote FOR the business combination and other proposals ahead of the deadline on October 6, 2025, at 11:59 p.m. ET Shareholders as of September 15, 2025, should vote their shares even if they no longer own themNEW YORK and AUSTIN, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Srl (“Terra Innovatum” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (“GSRT”) (Nasdaq: GSRT), a publicly traded special purpose acquisition company, remind GSRT shareholders to vote “FOR” their proposed business combination and all other proposals detailed in the definitive proxy statement/prospectus (the “Proxy Statement”). Shareholder Meeting Details GSR III Acquisition Corp. will hold its...

Continue reading

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease.Four key value-driving milestones are expected within 18 months, including clinical proof of concept in multiple indications. Estimated cash runway for combined company extends through 2027.Transaction projected to close in the first half of 2026. The combined company will be backed by OrbiMed and Torrey Pines and is expected to trade under the NASDAQ symbol “CLYD.”GERMANTOWN, Md. and ALTRINCHAM, United Kingdom, Sept. 30, 2025 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), an immunology and inflammation company focused on developing therapies...

Continue reading

Ten-League International Holdings Limited Reports Unaudited Financial Results for the First Six Months of Fiscal Year 2025

SINGAPORE, Sept. 30, 2025 (GLOBE NEWSWIRE) — Ten-League International Holdings Limited (NASDAQ: TLIH) (the “Company” or “Ten-League”), a Singapore-based provider of turnkey project solutions, today announced its unaudited financial results for the six months ended June 30, 2025. First Six Months of Fiscal Year 2025 Financial HighlightsRevenue was S$37.7 million (US$29.6 million) for the six months ended June 30, 2025, an increase of 21.6% from S$31.0 million for the same period last year.Gross profit was S$8.9 million (US$7.0 million) for the six months ended June 30, 2025, an increase of 67.7% from S$5.3 million for the same period last year.Gross profit margin was 23.5% for the six months ended June 30, 2025, an increase of 6.5 percentage points from 17.0% for the same period last year.Net income was S$2.4 million...

Continue reading

Nuvini Group Reports First Half 2025 Financial Results

~ Delivers 1H25 Free Cash Flow Growth of 16%, Reinforcing SaaS Model’s Efficiency ~ ~ Recurring Revenue Now 92.2% of Total Revenues, Firmly Establishing the Nuvini as a Pure Play SaaS Company ~ ~ Churn Continues on Successful Downward Trend ~ ~ Nuvini CEO Pierre Schurmann to Host Investor Webinar on Tuesday, September 30th, 2025 at 10:00a.m. Eastern Time ~ NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), the leading serial acquirer and operator of B2B SaaS companies in Latin America, today announced its financial results for the first half of 2025, highlighting increasing cash flow generation and efficiency through AI, streamlining the portfolio by shedding businesses outside our cash flow priorities, while properly preparing the Company to scale through new acquisitions. First...

Continue reading

Verisk Introduces New AI Tools to Streamline the Property Claims Experience

XactAI brings new automated capabilities to Verisk’s Xactware, a leading software for claims professionals JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) — Verisk (Nasdaq: VRSK), a leading data analytics and technology provider to the global insurance industry, today announced the launch of XactAI: a suite of capabilities powered by artificial intelligence that are purpose-built to enhance efficiency, consistency, and speed in claims handling. Now available as part of the Xactware suite of products for property claims, XactAI uses artificial intelligence and generative AI to automate processes such as summarizing complex data and organizing associated documentation. It also offers advanced workflow features to support participants in the lifecycle of a claim including insurance professionals, adjusters and contractors. By supporting...

Continue reading

STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis

HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a new peer-reviewed study in Lasers in Medical Science that reinforces the Company’s commitment to personalized medicine. The study demonstrates that treatment using the Company’s XTRAC 308nm Excimer Laser in combination with 0.1% tacrolimus ointment significantly improves outcomes in patients with plaque-type psoriasis compared to topical monotherapy. The study, titled “Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis,” was authored by Xiaobin Gao,...

Continue reading

Xeriant Initiates Certification Process with September Production of NEXBOARD Panels

BOCA RATON, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) — Xeriant, Inc. (OTCQB: XERI) (“Xeriant” or “the Company”), a company focused on the discovery, development, and commercialization of advanced materials and transformative technologies, today announced the successful completion of its September production run for NEXBOARD™, the Company’s next-generation eco-friendly composite construction panel. This limited production was primarily for the purpose of officially starting the certification process and for providing samples to the dozens of prospective clients involved in the construction industry. A representative from the certification testing agency was present at the contract manufacturer to document the manufacturing process and quality control procedures. “The batch we ran last week showed that NEXBOARD can...

Continue reading

Issuance of RIKS 34 1016

In relation to the switch auction of ÍL Fund today, the Icelandic Treasury will issue RIKS 34 1016 (ISIN: IS0000037737) in the nominal amount of 1,420,000,000 kr. The government bonds are subject to the “General terms and conditions for Icelandic Government bonds” and “Specific terms” for the bond series, which can be accessed on the Government Debt Management website, www.lanamal.is.

Continue reading

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that will be immediately exercisable upon issuance and will expire five years from the effective date of a registration statement registering for resale...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.